WO2012151272A3 - Vaccination avec des lymphocytes t à l'aide de vecteurs viraux par rupture épidermique mécanique - Google Patents

Vaccination avec des lymphocytes t à l'aide de vecteurs viraux par rupture épidermique mécanique Download PDF

Info

Publication number
WO2012151272A3
WO2012151272A3 PCT/US2012/036114 US2012036114W WO2012151272A3 WO 2012151272 A3 WO2012151272 A3 WO 2012151272A3 US 2012036114 W US2012036114 W US 2012036114W WO 2012151272 A3 WO2012151272 A3 WO 2012151272A3
Authority
WO
WIPO (PCT)
Prior art keywords
vaccine
mechanically disrupted
viral vectors
virus
via mechanical
Prior art date
Application number
PCT/US2012/036114
Other languages
English (en)
Other versions
WO2012151272A2 (fr
Inventor
Thomas S. Kupper
Luzheng Liu
Rachael A. Clark
Original Assignee
Tremrx, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/099,235 external-priority patent/US8691502B2/en
Application filed by Tremrx, Inc. filed Critical Tremrx, Inc.
Publication of WO2012151272A2 publication Critical patent/WO2012151272A2/fr
Publication of WO2012151272A3 publication Critical patent/WO2012151272A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Dans la présente invention, on utilise des virus atténués déficients en termes de réplication tels que des virus de la vaccine pour livrer un antigène exogène viral, bactérien, parasite ou tumoral à un tissu épidermique tel que la peau, les poumons ou le tractus gastrointestinal, qui a été mécaniquement rompu, suivant une quantité efficace pour éliciter ou stimuler une réponse immune médiée par la cellule. Le tissu épidermique peut être mécaniquement rompu au moyen d'un dispositif tel qu'une aiguille de scarification ou un dispositif abrasif. L'épiderme peut être mécaniquement rompu avant, en même temps ou immédiatement après l'administration du vaccin. Le vaccin peut être utilisé pour induire une immunité contre un agent pathogène, tel qu'un virus, une bactérie ou un parasite ou encore contre un cancer chez un individu qui est déjà atteint d'un cancer ou présente un risque de le développer. Dans certains modes de réalisation, une molécule de costimulation, un facteur de croissance, un adjuvant et/ou une cytokine est administré avant, en même temps ou après le vaccin viral. Dans certains modes de réalisation, la molécule de costimulation est co-exprimée avec l'antigène par le virus.
PCT/US2012/036114 2011-05-02 2012-05-02 Vaccination avec des lymphocytes t à l'aide de vecteurs viraux par rupture épidermique mécanique WO2012151272A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/099,235 US8691502B2 (en) 2008-10-31 2011-05-02 T-cell vaccination with viral vectors via mechanical epidermal disruption
US13/099,235 2011-05-02

Publications (2)

Publication Number Publication Date
WO2012151272A2 WO2012151272A2 (fr) 2012-11-08
WO2012151272A3 true WO2012151272A3 (fr) 2012-12-27

Family

ID=46168616

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/036114 WO2012151272A2 (fr) 2011-05-02 2012-05-02 Vaccination avec des lymphocytes t à l'aide de vecteurs viraux par rupture épidermique mécanique

Country Status (1)

Country Link
WO (1) WO2012151272A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3480307T (lt) * 2016-05-30 2021-09-27 Astellas Pharma Inc. Naujas genetiškai modifikuotas raupų virusas
US20190336552A1 (en) 2016-05-30 2019-11-07 Astellas Pharma Inc. Genetically engineered vaccinia viruses
US10888594B2 (en) 2016-05-30 2021-01-12 National University Corporation Tottori University Genetically engineered vaccinia viruses
CA3113965A1 (fr) 2018-09-26 2020-04-02 Astellas Pharma Inc. Therapie anticancereuse dans laquelle un virus de la vaccine oncolytique et un inhibiteur des points de controle immunitaire sont utilises en combinaison, et composition pharmaceu tique et medicament combine utilises dans celle-ci
WO2023077147A2 (fr) * 2021-11-01 2023-05-04 Pellis Therapeutics, Inc. Vaccins à lymphocytes t pour patients présentant une immunité humorale réduite
WO2023220283A1 (fr) * 2022-05-12 2023-11-16 Pellis Therapeutics, Inc. Adjuvant de poxvirus pour vaccination par lymphocytes t
CN114748627B (zh) * 2022-05-13 2023-10-27 中国医学科学院北京协和医院 可溶性cd58在胰腺癌预防和治疗中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0180490A1 (fr) * 1984-09-12 1986-05-07 AGENCE NATIONALE DE VALORISATION DE LA RECHERCHE (A.N.V.A.R.) Etablissement public de droit français Molécule synthétique contenant une pluralité d'épitopes distincts, procédé pour son obtention et application à la production de polyvaccins
GB2322130A (en) * 1997-02-13 1998-08-19 Secr Defence Simian herpes B virus glycoprotein D and its use in recombinant viral vaccines
WO2005103303A2 (fr) * 2004-04-13 2005-11-03 Alza Corporation Appareil et procede d'administration transdermique de multiples vaccins
US7378101B2 (en) * 2001-12-21 2008-05-27 Pfizer, Inc. Vaccine for periodontal disease

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2444713A1 (fr) 1978-12-18 1980-07-18 Pasteur Institut Procede de production d'un adn comprenant le genome du virus de l'hepatite b et vecteur le comportant
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
DE10399032I1 (de) 1987-08-28 2004-01-29 Health Research Inc Rekombinante Viren.
CA1340203C (fr) 1987-09-16 1998-12-15 Noboru Yanagida Virus de la variole aviaire, recombinant
CA1341245C (fr) 1988-01-12 2001-06-05 F. Hoffmann-La Roche Ag Virus recombinant de la vaccine derive du virus modifie ankara
WO1991019803A1 (fr) 1990-06-19 1991-12-26 Applied Biotechnology, Incorporated Particules virales autoassemblees defectueuses qui ne se propagent pas d'elles-memes
US6045802A (en) 1994-10-03 2000-04-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule
UA68327C2 (en) 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
US6706693B1 (en) 1997-08-13 2004-03-16 The Uab Research Foundation Vaccination by topical application of genetic vectors
US6503231B1 (en) 1998-06-10 2003-01-07 Georgia Tech Research Corporation Microneedle device for transport of molecules across tissue
MXPA02008873A (es) 2000-03-14 2003-02-10 Anton Mayr Cepa alterada del virus de vaccinia ankara modificado (mva).

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0180490A1 (fr) * 1984-09-12 1986-05-07 AGENCE NATIONALE DE VALORISATION DE LA RECHERCHE (A.N.V.A.R.) Etablissement public de droit français Molécule synthétique contenant une pluralité d'épitopes distincts, procédé pour son obtention et application à la production de polyvaccins
GB2322130A (en) * 1997-02-13 1998-08-19 Secr Defence Simian herpes B virus glycoprotein D and its use in recombinant viral vaccines
US7378101B2 (en) * 2001-12-21 2008-05-27 Pfizer, Inc. Vaccine for periodontal disease
WO2005103303A2 (fr) * 2004-04-13 2005-11-03 Alza Corporation Appareil et procede d'administration transdermique de multiples vaccins

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KANTOR J ET AL: "IMMUNOGENICITY AND SAFETY OF A RECOMBINANT VACCINIA VIRUS VACCINE EXPRESSING THE CARCINOEMBRYONIC ANTIGEN GENE IN A NONHUMAN PRIMATE", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 52, 15 December 1992 (1992-12-15), pages 6917 - 6925, XP000605381, ISSN: 0008-5472 *

Also Published As

Publication number Publication date
WO2012151272A2 (fr) 2012-11-08

Similar Documents

Publication Publication Date Title
WO2012151272A3 (fr) Vaccination avec des lymphocytes t à l'aide de vecteurs viraux par rupture épidermique mécanique
Zhang et al. Effect of vaccine administration modality on immunogenicity and efficacy
Giudice et al. Needle-free vaccine delivery
WO2007022151A3 (fr) Immunisation d'oiseaux par administration de vaccins a vecteurs non repliquants
Fernando et al. Influenza nucleoprotein DNA vaccination by a skin targeted, dry coated, densely packed microprojection array (Nanopatch) induces potent antibody and CD8+ T cell responses
JP2012041355A5 (fr)
BR112013012555A2 (pt) peptídeos imunogênicos para o uso na prevenção e/ou no tratamento de doenças infecciosas, doenças autoimunes, respostas imunes a alofatores, doenças alérgicas, tumores, rejeição a enxertos e respostas imunes contra vetores virais usados para a terapia de genes ou na vacinação de genes
WO2011063336A3 (fr) Site secondaire de stimulation d'antigène pour vaccination thérapeutique
WO2010037027A3 (fr) Immunisation d'oiseaux par administration mucosale de vaccins portés sur vecteur et incapables de se répliquer
EA201201203A1 (ru) Терпимое и минимально инвазивное устройство электропорации кожи
Kichaev et al. Electroporation mediated DNA vaccination directly to a mucosal surface results in improved immune responses
PH12015502844B1 (en) Mammalian milk osteopontin for enhancing immune responsiveness
WO2010045431A3 (fr) Formulations de poudres sèches, vaccins et procédés
Johansen et al. Intralymphatic immunotherapy and vaccination in mice
JP2017537106A5 (fr)
WO2023077147A3 (fr) Vaccins à lymphocytes t pour patients présentant une immunité humorale réduite
MX2021001288A (es) Vacunacion con microvesiculas derivadas de celulas tumorales para tratamiento de cancer.
Lisziewicz et al. The potential of topical DNA vaccines adjuvanted by cytokines
WO2012103510A8 (fr) Vaccin de primovaccination et de vaccination de rappel avancé
JP2016514114A5 (fr)
Pattani et al. Microneedle mediated intradermal delivery of Adjuvanted recombinant HIV-1 CN54gp140 effectively primes mucosal boost inoculations
Johansen et al. Administration routes for the delivery of vaccines and immunotherapeutics
Rappuoli et al. Novel immunologic adjuvants
Vazquez et al. Antigen Formulations and Routes of Immunization Drive the Magnitude and Quality of HIV-specific Mucosal Immune Responses in Mice
Phelip et al. Chimeric Nod2/TLR2 Ligand Amplifies HIV-1 Gag p24-specific Mucosal and Systemic Immune Responses after Sub Cutaneous Immunization in Mice

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12723774

Country of ref document: EP

Kind code of ref document: A2

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12723774

Country of ref document: EP

Kind code of ref document: A2